Proactive: Race Oncology At 12-Month High On Promising Preclinical Results For Drug Combination In Multiple Myeloma Treatment
Proactive reports that Race has hit a new 12-month high on fielding some strong preclinical findings on the efficacy of lead asset bisantrene in treating multiple myeloma.
Race CEO Dr Daniel Tillett commented: “The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib, is worthy of further investigation.”
Read the full article here.
